The authors recently identified a data tabulation coding error for patients with prior topical therapy for vitiligo. The original coding for prior topical therapy did not specify “for vitiligo” and incorrectly included non-topical corticosteroids. The coding was corrected, and data were re-tabulated. Data in Table 1 for prior topical therapy for vitiligo are updated, and a footnote was added to clarify that prior topical therapy included topical corticosteroids or topical calcineurin inhibitors. The prior topical therapy for vitiligo subgroup data in Supplementary Figure S2 was updated to present the corrected data for this subgroup analysis.
Table 1.
Demographics and baseline characteristics of the intention-to-treat population (N = 185).
| PBO (n = 46) | UPA 6 mg (n = 49) | UPA 11 mg (n = 47) | UPA 22 mg (n = 43) | |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Female | 29 (63.0%) | 26 (53.1%) | 34 (72.3%) | 26 (60.5%) |
| Male | 17 (37.0%) | 23 (46.9%) | 13 (27.7%) | 17 (39.5%) |
| Age, years | ||||
| Mean (SD) | 46.8 (10.48) | 45.1 (11.68) | 45.5 (11.90) | 48.2 (11.13) |
| Median (range) | 47.5 (18–64) | 45.0 (19–66) | 45.0 (22–65) | 49.0 (19–65) |
| Age group, n (%) | ||||
| ≤50 years | 26 (56.5%) | 28 (57.1%) | 28 (59.6%) | 25 (58.1%) |
| >50 years | 20 (43.5%) | 21 (42.9%) | 19 (40.4%) | 18 (41.9%) |
| BMI, kg/m2, mean (SD) | 27.3 (8.1) | 27.6 (5.7) | 27.5 (6.6) | 27.9 (5.8) |
| Race, n (%)a | ||||
| White | 34 (77.3%) | 35 (72.9%) | 36 (76.6%) | 33 (78.6%) |
| Black or African American | 4 (9.1%) | 3 (6.3%) | 3 (6.4%) | 1 (2.4%) |
| Asian | 6 (13.6%) | 6 (12.5%) | 7 (14.9%) | 6 (14.3%) |
| American Indian/Alaska Native | 0 | 0 | 0 | 1 (2.4%) |
| Native Hawaiian/Pacific Islander | 0 | 1 (2.1%) | 0 | 0 |
| Multiple | 0 | 3 (6.4%) | 1 (2.1%) | 1 (2.4%) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 5 (10.9%) | 6 (12.2%) | 4 (8.5%) | 5 (11.6%) |
| Fitzpatrick skin types, n (%) | ||||
| I | 3 (6.5%) | 1 (2.0%) | 1 (2.1%) | 1 (2.3%) |
| II | 11 (23.9%) | 13 (26.5%) | 15 (31.9%) | 14 (32.6%) |
| III | 17 (37.0%) | 17 (34.7%) | 19 (40.4%) | 17 (39.5%) |
| IV | 9 (19.6%) | 11 (22.4%) | 9 (19.1%) | 9 (20.9%) |
| V | 4 (8.7%) | 5 (10.2%) | 2 (4.3%) | 2 (4.7%) |
| VI | 2 (4.3%) | 2 (4.1%) | 1 (2.1%) | 0 |
| Country, n (%) | ||||
| United States | 23 (50.0%) | 26 (53.1%) | 24 (51.1%) | 21 (48.8%) |
| Canada | 6 (13.0%) | 11 (22.4%) | 8 (17.0%) | 7 (16.3%) |
| France | 12 (26.1%) | 10 (20.4%) | 11 (23.4%) | 11 (25.6%) |
| Japan | 5 (10.9%) | 2 (4.1%) | 4 (8.5%) | 4 (9.3%) |
| Duration since vitiligo diagnosis, years, mean (SD) | 18.5 (13.8) | 16.0 (11.4) | 17.9 (13.9) | 14.7 (13.7) |
| Active vitiligo, n (%) | 34 (73.9%) | 33 (67.3%) | 32 (68.1%) | 32 (74.4%) |
| Total-Physician Global Vitiligo Assessment of depigmentation, n (%)a | ||||
| None | 1 (2.3%) | 0 | 0 | 0 |
| Limited | 2 (4.7%) | 1 (2.1%) | 7 (15.6%) | 1 (2.5%) |
| Moderate | 17 (39.5%) | 24 (50.0%) | 19 (42.2%) | 21 (52.5%) |
| Extensive | 18 (41.9%) | 17 (35.4%) | 16 (35.6%) | 17 (42.5%) |
| Very extensive | 5 (11.6%) | 6 (12.5%) | 3 (6.7%) | 1 (2.5%) |
| Total-Patient Global Vitiligo Assessment of depigmentation, n (%)a | ||||
| None | 0 | 0 | 0 | 1 (2.3%) |
| Limited | 3 (6.8%) | 2 (4.1%) | 6 (12.8%) | 2 (4.7%) |
| Moderate | 21 (47.7%) | 21 (42.9%) | 13 (27.7%) | 12 (27.9%) |
| Extensive | 16 (36.4%) | 15 (30.6%) | 18 (38.3%) | 20 (46.5%) |
| Very extensive | 4 (9.1%) | 11 (22.4%) | 10 (21.3%) | 8 (18.6%) |
| F-VASI, mean (SD) | 1.04 (0.61) | 1.15 (0.77) | 1.02 (0.58) | 1.16 (0.66) |
| T-VASI, mean (SD) | 21.01 (16.95) | 20.99 (15.97) | 22.32 (18.18) | 21.84 (15.93) |
| T-VASI >10, n (%) | 32 (69.6%) | 33 (67.3%) | 30 (63.8%) | 31 (72.1%) |
| T-VASI ≥15, n (%) | 26 (56.5%) | 29 (59.2%) | 27 (57.4%) | 25 (58.1%) |
| VES, mean (SD) | 16.87 (16.54) | 18.77 (18.11) | 17.70 (15.31) | 20.16 (16.91) |
| Prior topical therapy, n (%)b | 19 (41.3%) | 15 (30.6%) | 15 (31.9%) | 15 (34.9%) |
| Prior phototherapy, n (%) | 12 (26.1%) | 4 (8.2%) | 9 (19.1%) | 10 (23.3%) |
BMI, body mass index; F-VASI, Facial Vitiligo Area Scoring Index; PBO, placebo; T-VASI, Total Vitiligo Area Scoring Index; UPA, upadacitinib; VES, Vitiligo extent score.
Values are based on non-missing values from randomised patients.
Prior topical corticosteroids or topical calcineurin inhibitors.
Supplementary Figure S2.
Percent change from baseline in F-VASI by subgroups. BMI, body mass index; F-VASI, Facial Vitiligo Area Scoring Index; LS, least squares; PBO, placebo; T-VASI, Total Vitiligo Area Scoring Index; UPA, upadacitinib. ∗p ≤ 0.10; ∗∗p ≤ 0.05; ∗∗∗p ≤ 0.01 versus PBO.
These corrections do not change the description, interpretation, or conclusions of the manuscript.